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The Fanconi anemia (FA) pathway is a major mechanism of homologous recombination DNA
repair. The functional readout of the pathway is activation through mono-ubiquitination of
FANCD2 leading to nuclear foci of repair. We have recently developed an FA triple-staining
immunofluorescence based method (FATSI) to evaluate FANCD2 foci formation in formalin
fixed paraffin-embedded (FFPE) tumor samples. DNA-repair deficiencies have been con-
sidered of interest in lung cancer prevention, given the persistence of damage produced by
cigarette smoke in this setting, as well as in treatment, given potential increased efficacy of
DNA-damaging drugs. We screened 139 non-small cell lung cancer (NSCLC) FFPE tumors
for FANCD2 foci formation by FATSI analysis. Among 104 evaluable tumors, 23 (22%)
were FANCD2 foci negative, thus repair deficient.To evaluate and compare novel-targeted
agents in the background of FA deficiency, we utilized RNAi technology to render several
lung cancer cell lines FANCD2 deficient. Successful FANCD2 knockdown was confirmed
by reduction in the FANCD2 protein. Subsequently, we treated the FA defective H1299D2-
down and A549D2-down NSCLC cells and their FA competent counterparts (empty vector
controls) with the PARP inhibitors veliparib (ABT-888) (5µM) and BMN673 (0.5µM), as
well as the CHK1 inhibitor Arry-575 at a dose of 0.5µM. We also treated the FA defective
small cell lung cancer cell lines H719D2-down and H792D2-down and their controls with
the BCL-2/XL inhibitor ABT-263 at a dose of 2µM. The treated cells were harvested at
24, 48, and 72 h post treatment. MTT cell viability analysis showed that each agent was
more cytotoxic to the FANCD2 knock-down cells. In all tests, the FA defective lung cancer
cells had less viable cells as comparing to controls 72 h post treatment. Both MTT and
clonogenic analyses comparing the two PARP inhibitors, showed that BMN673 was more
potent compared to veliparib. Given that FA pathway plays essential roles in response to
DNA damage, our results suggest that a subset of lung cancer patients are likely to be
more susceptible to DNA cross-link based therapy, or to treatments in which additional
repair mechanisms are targeted. These subjects can be identified through FATSI analysis.
Clinical trials to evaluate this therapeutic concept are needed.
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INTRODUCTION
With more than 159,480 deaths estimated in 2013, lung can-
cer is the number one cancer killer in the United States (1). The
standard first-line treatment of advanced lung cancer is platinum-
based chemotherapy. However, response rates to chemotherapy
vary widely among patients with the most common type, non-
small cell lung cancer (NSCLC), likely due to heterogeneity in
terms of platinum-sensitivity. Great efforts have been made to try
to identify molecular predictive markers of platinum resistance.
Inability to repair platinum adducts by the lack of nucleotide exci-
sion repair proteins (ERCC) has received considerable attention,
as a potential predictor of the efficacy of adjuvant platinum-based
chemotherapy. Results for this strategy, however, are conflict-
ing (2, 3), possibly due to poor discrimination by antibodies of
pertinent proteins isoforms.
Another major mechanism of DNA repair, related to homolo-
gous recombination, is through the Fanconi anemia (FA) pathway.
FA genes collaborate to form foci of DNA repair on chromatin fol-
lowing DNA damage or during S phase of cell cycle (4). Cells with
FA deficiency are hypersensitive to DNA damage agents such as
cisplatin and mitomycin C (MMC) (4), and tumors from patients
with germ line deficiency in some of the genes of this pathway have
been shown to be sensitive to DNA-damaging agents, as well as
inhibitors of other repair pathways, such as PARP inhibitors (4–6).
Additional studies have shown disruption of the FA cascade in
sporadic cancers (7–9). These disruptions may involve epigenetic
silencing of the FA-core complex, or mutations of one of several
FA genes. The FA pathway contains 16 complementation groups,
referred to as FA subtypes A, B, C, D1/BRCA2, D2, E, F, G, I, J, L, M,
N, O, P, and Q. Eight of these proteins (A, B, C, E, F, G, L, and M)
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are subunits of FA-core complex 1, a nuclear E3 ubiquitin ligase
(10–18).
The FA complex I functions to activate FANCD2 and FANCI by
mono-ubiquitinating the protein following response to DNA dam-
age (12, 13). The activated FANCD2 and FANCI proteins are sub-
sequently transported to subnuclear foci, which are thought to be
the sites of DNA repair and also contain BRCA1,FANCD1/BRCA2,
proliferating cell nuclear antigen (PCNA) and Rad51 (12, 15, 19).
Given that the FA pathway plays an essential role in response
to therapy-induced DNA interstrand cross-links, it is very plausi-
ble that cancers with defective FA pathway are more sensitive to
cross-link based therapy. Since FANCD2 foci formation is crit-
ical for cancer cells to resist MMC and cisplatin, the best way
to assess the functionality of this repair pathway as a whole is
by evaluating FANCD2 foci formation. We have developed an
FA triple-staining immunofluorescence based method (FATSI) to
evaluate FANCD2 foci formation, and have generated preliminary
data showing somatic deficiency of this pathway in tumors across
several organ sites (20).
Herein, we report our evaluation of FA deficiency in a series of
tumors from patients with NSCLC and the response of lung can-
cer cells with reduced FANCD2 expression (FANCD2 knock-down
cell) to treatment with inhibitors of PARP, CHK1, and BCL-2/XL.
MATERIALS AND METHODS
FA TRIPLE-STAINING IMMUNOFLUORESCENCE ANALYSIS
Human NSCLC samples were obtained from The Tissue Pro-
curement Shared Resource of the Ohio State University (OSU)
Comprehensive Cancer Center and The Cooperative Human Tis-
sue Network, Midwestern Division at OSU, after Institutional
Review Board (IRB) approval. FFPE tumor tissue was cut at 4µm,
placed on positively charged slides and stained with hematoxylin
and eosin. Additional sections for immunofluorescence staining
were placed in a 60°C oven for 1 h, cooled, deparaffinized, and
rehydrated through xylenes and graded ethanol solutions to water
in standard fashion. After antigen retrieval, the tissue sections were
incubated with a primary antibody cocktail of rabbit polyclonal
FANCD2 antibody (Novus Biologicals, Littleton, CO, USA) at a
dilution of 1:1000 and a monoclonal anti-Ki67 mouse antibody
(Dako, Carpenteria, CA, USA) at a dilution of 1:150, for 1 h at
room temperature. Sections were then co-incubated with a sec-
ondary antibody (FITC conjugated to anti-rabbit IgG and Alexa
fluor 594 donkey anti-mouse IgG, Invitrogen, Carlsbad, CA, USA)
at 1:1000 for 1 h at room temperature. All rinses were performed
on the autostainer with TBS-T. The sections were mounted on glass
slides using a 4′ 6-diamidino-2-phenylindole (DAPI)-containing
embedding medium (Vysis Dapi 1, Abbott Laboratories, Down-
ers Grove, IL, USA). Formalin fixed paraffin-embedded (FFPE)
FANCD2 foci negative cells (PD20) and foci positive cells (MCF-7
or FA corrected PD20) were used as controls on the sample slide
during the procedure. The slides were analyzed under a 100× oil
objective with a Nikon E-400 fluorescence microscope. See prior
publication (20).
GENERATION OF FANCD2 KNOCK-DOWN CELLS
Lung cancer cells A549, H1299 (NSCLC) H719, and H792 (small-
cell) were plated 24 h before transduction. At 60% confluence, cells
were transduced with FANCD2-specific shRNA-expressing and
puromycin-resistant lentiviral particles or control shRNA lentivi-
ral particles (Santa Cruz Biotechnology Inc.) according to the
manufacturer’s protocol. One day after incubation in medium
containing polybrene agent, these transduced cells were trans-
ferred to a dish that contains normal growth medium. The trans-
duced cells were selected in 4 mg/ml puromycin. To create stably
transduced cells, 100–200 transduced cells were cultured in a
100 mm dish, and medium was replaced with fresh puromycin-
containing medium every 3 days, until resistant colonies were
identified. Twenty colonies were picked for each cell line, and then
the colonies were expanded. Successful FANCD2 knockdown was
confirmed by western blot. Veliparib, ABT-263, and BMN673 were
obtained from Selleck Chemicals LLC; Arry-575 was provided by
Array BioPharma.
CELL VIABILITY ANALYSIS
Five thousand FA defective and control lung cancer cells
from each line (H1299E/H1299D2-down, A549E/A549D2-down,
H719E/H719D2-down, and H792E/H792D2-down) were seeded
in each well of a 96-well plate 24 h prior to treatment. Cells were
treated with the single agent at the designated dose (see Results).
Dimethylthiazolyl-2-5-diphenyltetrazolium bromide (MTT) dye
solution (Sigma, St. Louis, MO, USA) was added into the 96-well
plate 20 h post treatment. The plate was incubated at 37°C for
4 h, and the treatment terminated by adding stop solution (iso-
propanol with 0.04 N HCl). MTT was cleaved by live cells to a
colored formazan product. Absorbance at 560 nm wavelength was
recorded using a Bio-Rad micro plate reader 680 (Bio-Rad Labo-
ratories, Inc., Hercules, CA, USA). Each treatment was repeated in
quadruplicate. An averaged absorbance of blank values (contain-
ing all reagents except cells) was subtracted from all absorbance to
yield corrected absorbance. The relative absorbance of each sample
was calculated by comparing the average of corrected absorbance
with an average of corrected untreated control.
WESTERN IMMUNOBLOT ANALYSIS AND ANTIBODIES
Western immunoblot analysis was performed as described pre-
viously (21). Briefly, cells were digested with lysis buffer, which
contained 250 mM NaCl; 5 mM EDTA; 1% Igepal; 5 mM dithio-
threitol (DTT); 1 mM phenylmethylsulfonyl fluoride (PMSF); and
1% protease inhibitor cocktail (Sigma, Saint Louis, MO, USA).
Protein concentrations were evaluated using the Bradford reagent
(Bio-Rad, Hercules, CA, USA). Hundred micrograms of total pro-
tein was loaded onto NuPAGETM 4–12% Bis–Tris Gel (Invitrogen,
Carlsbad, CA, USA). Protein on the gels was electro-transferred
onto nitrocellulose membranes and blocked with blocking buffer
(5% of non-fat milk, 500 mM of NaCl, 20 mM Tris, and 0.1%
Tween-20). The membranes were incubated with primary anti-
bodies at 4°C overnight. After washing with TBS-T (blocking
buffer without milk) five times, 10 min each, the membranes
were incubated with anti-mouse Ig or anti-rabbit Ig horserad-
ish peroxidase linked to whole secondary antibodies (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) at room temperature for
1 h. After washing five times, 10 min each, a chemiluminescent
detection system (ECL western blotting detection reagents, GE)
was used to detect the secondary antibody. Finally, the membranes
Frontiers in Oncology | Thoracic Oncology December 2014 | Volume 4 | Article 368 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Duan et al. FA pathway dysfunction in lung cancer
were exposed to x-ray films. Antibodies used were: rabbit poly-
clonal FANCD2 antibody (Novus Biologicals, Littleton, CO, USA),
anti-tubulin monoclonal (Sigma, St. Louis, MI, USA).
RESULTS
FANCONI ANEMIA PATHWAY DEFICIENCY IN NON-SMALL CELL LUNG
CANCER TUMOR SAMPLES
We used the FATSI method to evaluate FANCD2 foci formation
or lack thereof in lung cancer samples. We screened a total of 139
NSCLC FFPE tumors; 104 were evaluable for FANCD2 foci status
(Figure 1). Eighty-one of the 104 (78%) evaluable tumors were
found FANCD2 foci positive and 23 (22%) were foci negative.
Forty-nine of the NSCLC samples were of adenocarcinoma
histology by morphology examination, 46 were squamous, 5 large
cell, and 4 of mixed histology. Thirteen (26.5%) adenocarcinomas
and seven (15.2%) squamous cell were foci negative. Two of the
five large cell carcinoma and one of four mixed histology were
foci negative. The frequencies may suggest that adenocarcinomas
tumors have higher percentage of FANCD2 foci negative tumors as
comparing to squamous cell carcinoma tumors. This observation
will need corroboration with larger sample size and adjustment
with other confirmatory tests, such as immunohistochemistry, not
available to us for this dataset.
GENERATION OF FANCD2 KNOCK-DOWN CELLS AND EVALUATION OF
SENSITIVITY TO PARP INHIBITORS
Non-small cell lung cancer cell lines A549, H1299, and small
cell H719, H792 were transduced with FANCD2-specific shRNA-
expressing and puromycin-resistant lentiviral particles, or control
shRNA lentiviral particles. To generate stably transduced cells, cells
were selected by puromycin. Successful FANCD2 knock-down
colonies were confirmed by western blot assessment of FANCD2
protein. Figure 2A illustrates four lung cancer cell lines with
reduced FANCD2 protein. We also evaluated the response of the
H1299E (H1299 cell transduced with empty vector) and FANCD2
knockdown (H1299D2-down) to treatment with cisplatin at a dose
of 5µg/ml, 72 h post treatment. We found that FANCD2 silencing
resulted in sensitization of cells to cisplatin (Figure 2B).
To evaluate the influence of defective FA pathway in regards
to cell viability following exposure to the PARP inhibitors veli-
parib (ABT-888) and BMN673, we treated the FA defective NSCLC
cell lines H1299D2-down and A549D2-down, as well as their FA
competent counterparts (H1299E and A549E) (empty vectors)
with veliparib at a dose of 5µM or BMN673 at dose of 0.5µM.
MTT assay was used for the cell viability analysis and an aver-
aged absorbance was recorded 24, 48, and 72 h post treatment.
Cell viability analysis showed that the FA defective H1299D2-
down cells had 80% of viable cells compared to non-treatment
controls 72 h post treatment with veliparib. In contrast, there was
no influence on viability of the H1299E cell with the same treat-
ment (Figure 3A). Both the A549D2-down cell and A549E cells
responded to some degree to the treatment with veliparib at 48
and 72 h post treatment. The A549D2-down cells had 68% viable
cells compared to 83% viable cells for the A549E cells, 72 h post
treatment (Figure 3B).
BMN673 is a new class of PARP inhibitor, which has in addi-
tion strong PARP1-DNA complex trapping function (22, 23). Cell
FIGURE 1 | Detection of FANCD2 foci formation in human lung tumors
by the FATSI staining analysis. The paraffin-embedded lung tumor tissues
sections were deparaffinized and rehydrated. The tissue sections were
incubated with a primary antibody cocktail of rabbit polyclonal FANCD2
antibody (Novus Biologicals, Littleton, CO, USA) at a dilution of 1:1000 and a
monoclonal anti-Ki67 mouse antibody (Dako, Carpenteria, CA, USA) at a
dilution of 1:150 for 1 h at room temperature. Sections then were incubated
with a secondary antibody cocktail containing FITC conjugated anti-rabbit
IgG and Alexafluor 594 donkey anti-mouse secondary for 1 h at room
temperature. The sections were mounted on glass slides using a 4′
6-diamidino-2-phenylindole (DAPI)-containing embedding medium (Vysis
Dapi 1, Abbott Laboratories, Downers Grove, IL, USA). The slides were
analyzed under a fluorescence microscope. (A) FANCD2 foci positive NSCL
tumor, and (B) FANCD2 foci negative NSCL tumor. Magnification: 1000×.
viability analysis showed that BMN673 was overall a more potent
inhibitor (10-fold difference in active doses) compared to veli-
parib. H1299 FANCD2 knock-down cancer cells were also more
sensitive to BMN673 compared to empty vectors transfected con-
trol cells (25 vs. 62% viable cells, respectively) 72 h post treatment
(Figure 3C). A549D2-down cell had 29% viable cells and the
A549E had 46% viable cells 72 h post treatment (Figure 3D). The
IC50 of BMN673 treated A549E cell was 0.64µM and the IC50
www.frontiersin.org December 2014 | Volume 4 | Article 368 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Duan et al. FA pathway dysfunction in lung cancer
FIGURE 2 | Creating FANCD2 knock-down cells and evaluating
response to cisplatin. (A) NSCLC cells H1299, A549, and small cell lung
cancer cells H719, H792 were plated. At 60% confluence, cells were
transduced with FANCD2-specific shRNA-expressing and
puromycin-resistant lentiviral particles or control shRNA lentiviral particles
(Santa Cruz Biotechnology Inc.) according to the manufacturer’s protocol.
The transduced cells were selected in 4 mg/ml puromycin to create stably
transduced cells with reduced FANCD2 expression. Successful FANCD2
knockdown was confirmed by western blot detection of the FANCD2
protein. C is a control cell and D is FANCD2 knock-down cell. (B) The
H1299E (H1299 was transfected with empty vector) and FANCD2
knock-down (H1299D2-down) lung cancer cells were treated with cisplatin
(5µg/ml) for 24, 48, and 72 h. The knock-down cell was more sensitive to
the treatment.
of A549D2-down was as low as 0.075µM 72 h post treatment.
The difference in the IC50 values between H1299E and H1299D2-
down cells is smaller with 1.78µM for the H1299E and 0.74µM
for the H1299D2-down.
To further investigate differential response to treatment with
PARP veliparib and BMN673 between FA defective and FA intact
lung cancer cells, we conducted clonogenic survival analysis.
A549D2-down/A549E cells were seeded in a six-well plate and
treated with veliparib (0.5µM) or BMN673 (0.5µM). Colonies
were stained with crystal violet and counted. Clonogenic sur-
vival analysis showed that veliparib was cytotoxic to the FA
defective A549D2-down cells (60% viable cells as compared to
non-treatment control), and the A549E had 78% viable cells
(Figure 4). Following treatment with BMN673 (0.5µM), the FA
defective A549D2-down cells were 22% viable as compared to
non-treatment control. A549E cells were 43% viable (Figure 4).
EFFECT OF FANCONI ANEMIA REPAIR PATHWAY INTEGRITY ON
RESPONSE TO CHECKPOINT INHIBITORS
DNA-repair-deficient tumor cells have been shown to accumulate
high levels of DNA damage. Therefore, the DNA-repair-deficient
cells are dependent on other compensatory DNA-repair pathway,
such as the CHK1-kinase pathway. FA defective cells are dependent
on this G2/M checkpoint for viability, since the checkpoint activa-
tion allows for the repair of damaged DNA prior to mitosis. CHK1
is activated by the ATR kinase in response to DNA damage that
stalls replication fork progression (24, 25). Defects in FA pathway
have been shown to be synthetic lethal with CHK1 inhibition or
genetic CHK1 depletion in human fibroblast and ovarian cancer
cells (24).
Arry-575 (GDC-0575) is a novel small molecule inhibitor of
CHK1, in FA-deficient lung cancer cells. We conducted a dosage
test on Arry-575 with H1299 cells, and found the IC50 values were
around 1 and 0.5µM for the H1299E and the H1299D2-down
cells 72 h post treatment. We treated the FA defective lung can-
cer cell lines H1299D2-down and the control cell H1299E with
Arry-575 at a dose of 0.5µM. MTT assay was used for cell viabil-
ity analysis and an averaged absorbance was recorded 24, 48, and
72 h post treatment. Cell viability analysis showed that Arry-575
was more cytotoxic to the H1299D2-down cancer cells. The FA
defective H1299D2-down cells had 38% of viable cells compared
to non-treatment controls 72 h post treatment. In contrast, there
were about 60% viable cells in the control cell line H1299E cells
(Figure 5A).
To evaluate potential synergy for the combination of PARP
inhibition and CHK1 inhibition, we treated the H1299D2-down
and the control cell H1299E with Arry-575 (0.5µM) and veliparib
(5µM) alone, or in combination for 72 h. MTT assay analysis
showed a similar portion of viable cell between the treatment of
Arry-575 alone and the combination (Figure 5B).
RESPONSE OF FANCD2 DEFECTIVE SMALL CELL LUNG CANCER CELLS
TO Bcl-2/Bcl-xL INHIBITION
Bcl-2 is a central apoptotic inhibitor, and overexpression is associ-
ated with tumor progression and treatment resistance in cancers.
Overexpression has been reported in up to 80% of small cell lung
cancers (SCLC). ABT-263 (navitoclax) is a potent and selective
inhibitor of Bcl-2 and Bcl-xL, disrupting their interactions with
pro-death proteins leading to the initiation of apoptosis (26, 27).
However, a recent phase II study of single-agent navitoclax showed
low rate of response to single-agent treatment in advanced and
recurrent SCLC (28). Thus, pre-selection of patients most likely
to derive benefit from BCL-2 inhibitors will be needed for further
development of these agents in SCLC.
To evaluate the influence of the FA pathway to treatment with
navitoclax, the FA defective H719D2-down and H792D2-down
cells as well as their FA competent counterparts (H719E and
H792E) were treated with navitoclax at a dose of 2µM. The treated
cells were then harvested at 6, 24, and 48 h post treatment. MTT
cell viability analysis showed that navitoclax was more cytotoxic to
the FA-deficient H719D2-down compared to its control (51 and
85% viable cells at 48 h, respectively) (Figure 6A). Similarly, the
H792D2-down small cell lung cancer cells had 58% viable cells
and the H792E had 86% viable, 48 h post treatment (Figure 6B).
COMPENSATORY ACTIVATION OF ALTERNATIVE DNA-REPAIR
PATHWAYS FOLLOWING EXPOSURE TO VELIPARIB
We performed Western immunoblot analysis to evaluate the
expression level of PAR, FancD2, and ERCC1, in the human cancer
cell lines H1299 following exposure to veliparib. PAR protein level
was reduced at 6 h post veliparib exposure (5µM) and maintained
at low levels through 48 h in the H1299 cells. However, FANCD2
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FIGURE 3 | MTT assay analysis of cell survival in FA-deficient and
competent NSCLC cells post treatment with the PARP inhibitors
veliparib and BMN673. We treated the FA defective and control lung cancer
cell lines H1299D2-down/H1299E and A549D2-down/A549E with veliparib
(5µM) or BMN673 (0.5µM). MTT assay was used for the cell viability analysis
and an averaged absorbance was recorded 24, 48, and 72 h post treatment.
Cell viability analysis showed both control cells H1299E and A549E had no or
limited response, and the FA defective cells H1299D2-down and
A549D2-down had a mild response to the treatment of veliparib (A,B).
BMN673 had more cytotoxicity (C,D).
FIGURE 4 | Clonogenic analysis cell survival for A549E and
A549D2-down cells treated with veliparib (0.5µM) or BMN673
(0.5µM): A549E and A549D2-down cells were seeded in a six-well plate
and treated with or without veliparib (0.5µM) or BMN673 (0.5µM) for
8 days. Colonies were stained with crystal violet and counted. Clonogenic
survival analysis showed that veliparib alone was cytotoxic to A549 cells.
The FA defective A549D2-down cells had 60% viable cells, and the A549E
had 78% viable cells as compared to non-treatment control cells. Post
treatment with BMN673 (0.5µM), the FA defective A549D2-down cells has
22% viable cells, and the A549E had 43% viable cells as compared to
non-treatment control.
and ERCC1 protein expression was simultaneously elevated in
these cells post treatment with veliparib (Figure 7).
DISCUSSION
DNA repair is essential for cells to maintain genome stabil-
ity. There is a growing appreciation that defects in homologous
recombination repair underlie hereditary and sporadic tumori-
genesis, conferring a survival advantage to cancer cells. How-
ever, this deficiency may increase sensitivity of tumors to certain
DNA-damaging agents. Homologous recombination deficiency
may therefore prove to be a target of cancer treatment, as long
as appropriate biomarkers become available to identify patients
with these tumors (29). Our recently developed FATSI method to
evaluate FANCD2 foci formation, which is capable of evaluating
the functionality of the pathway using FFPE tumor samples (20)
could represent such a test. This method is suitable for large scale
screening to select cancer patients most suitable for treatment with
DNA-damaging agents. In addition, the therapeutic window for
certain novel molecular targeted agents such as PARP inhibitors,
checkpoint inhibitors, and BCL-2/xL inhibitors may be larger for
the FA-deficient tumors because the DNA lesions induced can-
not be efficiently repaired and will eventually lead to the cells
undergoing apoptosis (29, 30).
We found that 22% of NSCLC tumors examined had func-
tional deficiency in the FA pathway and that cells with deficient FA
pathway were more sensitive to treatment with PARP inhibitors.
Both MTT and clonogenic analyses showed BMN673 was more
potent compared to veliparib. This may be due to veliparib having
a much weaker ability to trap PARP–DNA complexes despite its
great activity as a PARP catalytic inhibitor (23). Furthermore, our
studies showed that lung cancer cells with deficient FA pathway
were more sensitive to treatment with a CHK1-kinase pathway
inhibitor and a BCL-2/XL inhibitor.
Of concern are the results showing that veliparib up-regulated
FA and nucleotide excision repair proteins in the H1299 FA wild
type cells. Thus, treatment with veliparib in repair wild type
cells may plausibly influence resistance to DNA targeting cyto-
toxic chemotherapy. Cancers with defective FA or NER pathways,
which are incapable of mounting a compensatory response, may
represent a better target for veliparib (or BMN673) alone or in
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FIGURE 5 | Cell survival of FA defective lung cancer cells to treatment
of CHK1 inhibitor as single agent or in combination with veliparib. The
FA defective lung cancer cell lines H1299D2-down and the control cell
H1299E (transfected with empty vectors) were treated with Arry-575 at
dose of 0.5 M. MTT assay was used for the cell viability analysis and an
averaged absorbance was recorded 24, 48, and 72 h post treatment. Cell
viability analysis showed the Arry-575 was more cytotoxic to these
H1299D2-down cancer cells. The FA defective H1299 cells had 38% of
viable cells compared to non-treatment controls 72 h post treatment. In
contrast, there were 60% viable cells in the H1299E cells (A). To evaluate
the effect of the combination of PARP inhibitor and CHK1 inhibitor, we also
treated the H1299D2-down/H1299E cells with Arry-575 (0.5 M) and
veliparib (5 M) alone, or in combination for 72 h. A similar proportion of
viable cells after treatment of Arry-575 alone and combination of Arry-575
and ATB888 was recorded (B).
combination with DNA targeted cytotoxic chemotherapy. It is
unclear at this point if targeting two additional repair mecha-
nisms in the setting of FA dysfunction will be better than one
in tumor shrinkage and/or delaying the appearance of resistance.
That is, for example, inhibiting base excision repair through PARP
inhibition/PARP trapping and nucleotide excision repair through
ERCC1 in FA-deficient tumors. It is possible that the risks of addi-
tional toxicities may outweigh any potential benefits. However,
these experiments are worth conducting but it would be optimal
to use best in class drugs.
The identification of patients with somatic functional defi-
ciency of the FA pathway in their tumors may also lead to a better
understanding of the specific genetic/epigenetic events that drive
the cancer in these patients, by selecting these patients for deep
DNA and RNA sequencing and methylome analysis. The genetic
instability caused by the repair deficiency may lead to additional
molecular changes that take over as drivers, a concept that have
been named non-oncogenic addiction or induced sustainability
(31, 32). Identification and inactivation of these added drivers may
result in an opportunity for synthetic lethality. Our laboratory is
pursuing this approach by performing RNAseq in FA-deficient
tumor archival material and in fresh biopsies from patients in
clinical trials of PARP inhibition.
FIGURE 6 | Analysis of cell viability post treatment of small cell lung
cancer cells with Bcl-2/Bcl-xL inhibitor ABT-263 (navitoclax). The FA
defective small cell lung cancer cells H719D2-down and H792D2-down and
their FA competent counterparts H719E and H792E were treated with
navitoclax at a dose of 2µM. The MTT assay was performed to determine
cell viability 6, 24, and 48 h post treatment. Each treatment was repeated in
quadruplets. An averaged absorbance of blank values (with no cells) was
subtracted from all absorbance to yield corrected absorbance. The relative
absorbance of each sample was calculated by comparing the average of
corrected absorbance with an average of corrected untreated control. Each
value presented in this figure was an average value obtained from four
measurements. The cell viability analysis showed that navitoclax was more
cytotoxic to both H719D2-down (A) and H792D2-down (B) FA defective
cells.
Resistance to DNA interactive agents and PARP inhibitor may
develop in patients with FA dysfunctional tumors through the
recovering of function after a period of treatment. It has been
reported that promoter methylation of several FA genes resulted
in deficiency in FA repair foci formation in human cancers (4, 33–
38). The plasticity of epigenetics changes may lead, for example,
to hypomethylation of these promoters with a resulting recovery
of FA function. Other reported mechanisms of function recovery
include post-treatment restorative acquired mutations in previ-
ously dysfunctional repair genes (39, 40). Thus, it is of tantamount
importance that any patient selection for clinical trials evaluating
therapeutics in FA-deficient tumors is based on screening of recent
tumor material, not separated by intervening treatment. Requiring
biopsies once progression occurs will offer invaluable information
regarding the mechanisms mediating acquired resistance.
In summary, the FATSI method shows that a proportion of
lung cancer patients have tumors with FA deficiency. We have also
demonstrated that lung cancer cells with defective FA pathway
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FIGURE 7 | Western blot analysis of FANCD2 and ERCC1 expression in
lung cancer cell H1299 following treatment with veliparib. PAR protein
level was reduced at 6 h post veliparib 5µM exposure and maintained at
low levels through 48 h in the H1299 cells. However, FANCD2 and ERCC1
protein expression raised simultaneously in these cells post treatment with
veliparib. The data suggest that veliparib induces compensatory activation
of alternative DNA-repair pathways. C is control (without treatment).
were more sensitive to PARP inhibitors and increase the therapeu-
tic window of other molecularly targeted agents. Clinical studies
are needed to validate the therapeutic potential of these preclinical
findings.
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